This convincing preclinical data has led to implementation of the CAR2BRAIN phase I clinical trial (NCT03383978) treating recurrent or refractory HER2-positive GBM patients with HER2-specific CAR NK cells derived from the NK-92 cell line (Burger et al., 2016). Here, ERBB2 is linked to glioblastoma.